key: cord-0804714-c8k6xqj6
authors: nan
title: Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries
date: 2021-01-30
journal: Lancet
DOI: 10.1016/s0140-6736(21)00001-5
sha: 9a950c031ac9c15e6e68479fa81539c3c7640969
doc_id: 804714
cord_uid: c8k6xqj6

BACKGROUND: 80% of individuals with cancer will require a surgical procedure, yet little comparative data exist on early outcomes in low-income and middle-income countries (LMICs). We compared postoperative outcomes in breast, colorectal, and gastric cancer surgery in hospitals worldwide, focusing on the effect of disease stage and complications on postoperative mortality. METHODS: This was a multicentre, international prospective cohort study of consecutive adult patients undergoing surgery for primary breast, colorectal, or gastric cancer requiring a skin incision done under general or neuraxial anaesthesia. The primary outcome was death or major complication within 30 days of surgery. Multilevel logistic regression determined relationships within three-level nested models of patients within hospitals and countries. Hospital-level infrastructure effects were explored with three-way mediation analyses. This study was registered with ClinicalTrials.gov, NCT03471494. FINDINGS: Between April 1, 2018, and Jan 31, 2019, we enrolled 15 958 patients from 428 hospitals in 82 countries (high income 9106 patients, 31 countries; upper-middle income 2721 patients, 23 countries; or lower-middle income 4131 patients, 28 countries). Patients in LMICs presented with more advanced disease compared with patients in high-income countries. 30-day mortality was higher for gastric cancer in low-income or lower-middle-income countries (adjusted odds ratio 3·72, 95% CI 1·70–8·16) and for colorectal cancer in low-income or lower-middle-income countries (4·59, 2·39–8·80) and upper-middle-income countries (2·06, 1·11–3·83). No difference in 30-day mortality was seen in breast cancer. The proportion of patients who died after a major complication was greatest in low-income or lower-middle-income countries (6·15, 3·26–11·59) and upper-middle-income countries (3·89, 2·08–7·29). Postoperative death after complications was partly explained by patient factors (60%) and partly by hospital or country (40%). The absence of consistently available postoperative care facilities was associated with seven to 10 more deaths per 100 major complications in LMICs. Cancer stage alone explained little of the early variation in mortality or postoperative complications. INTERPRETATION: Higher levels of mortality after cancer surgery in LMICs was not fully explained by later presentation of disease. The capacity to rescue patients from surgical complications is a tangible opportunity for meaningful intervention. Early death after cancer surgery might be reduced by policies focusing on strengthening perioperative care systems to detect and intervene in common complications. FUNDING: National Institute for Health Research Global Health Research Unit.

. Proportion of all patients who sustained specific complications, stratified by cancer-type and country income group. . 5 Figure S4 . Adjusted proportion of patients dying or sustaining a major complication or any complication by day 30 Figure S7 . Hospital type and facilities for centres treating colorectal and gastric cancer, stratified by country income group. ..... 41 Table S10 . Summary of hospital care services for centres treating gastric and colon cancer stratified by country income group. . 42 Table S11 . 30 Figure S1 . Missing values map. Missing values for main explanatory and dependent variables by observation. Figure S2 . Stage of presentation, 30-day mortality, and 30-day complications by cancer and country income group. Panels A, B and C are replicated from Figure 3 to aid comparisons. A, proportion of patients enrolled by cancer stage by country income group. B, proportion of patients dying or sustaining a major complication or any complication by day 30 after surgery stratified by country income group. C, proportion of patients sustaining a major complication who died within 30 days. D, E, F, 30-day mortality (D), major complication (E), and any complication (F) stratified by cancer type, cancer stage, and country income group. Figure S3 . Proportion of all patients who sustained specific complications, stratified by cancer-type and country income group.

Ordered by overall frequency. CD, Clavien-Dindo complication grade; OSI, organ space infection. See appendix pp 21-22 for detailed table. Figure S4 . A, adjusted proportion of patients dying or sustaining a major complication or any complication by day 30 after surgery stratified by country income group. B, proportion of patients sustaining a major complication who died within 30 days. Proportions are adjusted for patient complications using multivariable (reduced) logistic regression models in Table  S6A/B/C (breast), Table S7A/B/C (colorectal), Table S8A /B/C (gastric), pp 23-39. Figure S5 . A, method of determination of 30-day follow-up variables. B, basis for cancer diagnosis stratified by cancer type and country income group.

A B Essential TNM Classification of Malignant Tumours (eTNM), as defined by the Union for International Cancer Control (UICC), for breast cancer: Tis, No invasive cancer (e.g. DCIS); L1, Tumour £2 cm in size (T1); L2, Tumour >2 cm in size (T2/T3); A, Inflammatory cancer, chest wall invasion or ulceration present (T4); R1, 1 to 3 nodes involved inside axilla but none outside axilla (N1); R2, >3 nodes involved inside axilla or nodal involvement outside axilla (N2/N3); M+, Metastases present (M1). ASA, American Society of Anesthesiologists operative risk grade; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; HIV, human immunodeficiency virus; SNLB, sentinel lymph node biopsy; SD, standard deviation. Data are n (%). Figure S6A . Comparison between preoperative clinical and postoperative final pathological staging.

Preoperative clinical staging performed using Essential TNM Classification of Malignant Tumours (eTNM), as defined by the Union for International Cancer Control (UICC). Figure S6B . Capacity to rescue from major complication: sensitivity analysis using postoperative final pathological staging. A, multilevel logistic regression model for predictors of death after major complication in colorectal and gastric cancer. B, proportion of 30-day mortality variation explained at the level of patient/disease, hospital, country, and country income group, in patients with colorectal or gastric cancer who died after major complication. The "variance explained" at each of the 4 levels of the model (marginal pseudo-R 2 ) is expressed as a proportion of the total "variance explained" (conditional pseudo-R 2 ). WHO, World Health Organisation; SNLB, sentinel lymph node biopsy. Data are n (%). 

Yes, resulting in death (CD 5) 

10.1 (8.8) 8.9 (6.8) 9.0 (7.1) 12.0 (31.3) 9.9 (6.2) 10.3 (7.0) CD, Clavien-Dindo complication grade. OSI, organ space infection. OR, odds ratio; WB, World Bank; ASA, American Society of Anesthesiologists operative risk grade; BMI, Body Mass Index; ECOG, Eastern Cooperative Oncology Group; SD, standard deviation. Data are n (%) and OR (95% confidence interval, p-value). Multilevel model includes hospital and country as random intercepts. Yes, critical care admission &/or intervention (CD 4) 1 (3.7) 1 (10.0) 2 (7.1) Yes, resulting in death (CD 5) 3 (11.1) 1 (10.0) 2 (7. CD, Clavien-Dindo complication grade; OSI, organ space infection. Data are n (%). Figure S7 . Hospital type and facilities for centres treating colorectal and gastric cancer, stratified by country income group.

MDT, multidisciplinary team. Table S11. 30-day mortality in patients who sustained a major complication. Capacity to rescue models. Figure 5A uses the multilevel model. Figure 5C and 5D use the multivariable and multivariable including postoperative care infrastructure models. OR, odds ratio. ASA, American Society of Anesthesiologists operative risk grade; ECOG, Eastern Cooperative Oncology Group; SD, standard deviation. Data are n (%) and OR (95% confidence interval, p-value). Multilevel model includes hospital and country as random intercepts. Table S12 . 3-way mediation decomposition of proportion of effect of country income group on 30-day mortality mediated by the absence of postoperative care infrastructure. No significant exposure-mediator interaction was seen so a two-way decomposition is presented. Variables in the Table S11 multivariable model were included as covariates. Given that the potential mediator in this case is a hospital-level factor, it was assumed that there was no causal relationship between this and covariates at the patient level. Similarly, no mediator-outcome confounders were specified. These models therefore represent the change in country income group coefficients on the introduction of the postoperative care infrastructure variable. Uncertainty was determined using bootstrap resampling (5000 draws) and confidence intervals constructed using percentiles. 

Case ascertainment was performed by independent validators in contributing hospitals to determine the proportion of patients meeting the inclusion criteria who were actually enrolled. Validators were asked to provide this information prior to receiving patient-level information for later validation steps. Case ascertainment was performed in a random sample of 265 hospitals (high 156, upper middle 48, low/lower middle 61, as defined by the World Bank country income groups) in 69 countries representing 1060 hospital-weeks of data collection. The validation cohort were representative of the primary data collected by 838 mini-teams ( Figure S6 ).

In primary data collection for the main study, there were 3669 patients included across hospitals selected for validation. Validators identified 3805 cases that fulfilled inclusion criteria for the validation period, equating to a case ascertainment rate of 96.4% (3669/3805). There was no difference in case ascertainment rates between World Bank country income groups (chi-squared statistic 1.04, df 2, p=0.595).

There was little variability in case ascertainment across all hospitals (min 30%, lower quartile 100%, median 100%, upper quartile 100%, max 100%) ( Figure S7 ). Figure S8 . Distribution of patients enrolled per hospital in validation sample. Figure S9 . Case ascertainment. Correlation of number of patients fulfilling inclusion criteria identified by validators against those included in primary data collection. Dotted lines represent 50% and 95% concordance.

Data accuracy A subset of variables was re-collected by data validators who were independent of the primary data collection process. Following case ascertainment (above), validators were provided with the following patient variables: hospital ID, age, gender, date of admission, date of operation, cancer type and primary operation name. These data were complete in the primary dataset. Using this information, validators were asked to confirm the following variables from the patient's paper or electronic notes: two patient variables (age and gender), one disease-specific variable (pathological stage), two operation variables (urgency and operative intent), and two outcome measures (30-day major complication and 30-day mortality).

Availability of sampled variables is detailed in table S16. Overall availability of variables for validation was good (Table S16) . However, there was some difficulty in low/lower middle-income countries, with some validators commenting about on the lack of availability of reliable written notes. This pattern was reflected particularly in operation records. The ability of validators to identify outcome measures was lower across all countries (30-day major complication available, high 87.9%, upper middle 86.6%, low/lower middle 79.6% World Bank income group; Table S16 ). Data accuracy: continuous data Age was the only continuous variable which was validated. Validator versus primary data were highly correlated (Pearson correlation coefficient 0.997, 95% CI 0.996 to 0.997) (Table S17; Figure S8 ). Figure S10 . Correlation of patient age in validation vs primary datasets (n=4520)

Data accuracy: categorical data For categorical variables, agreement between validation and primary data is described using the Cohen's kappa coefficient. Guidelines on the interpretation of agreement with the kappa coefficient are poor (<0.20), fair (0.20 to 0.40), moderate (0.41 to 0.60), good (0.61 to 0.80), and very good (0.80 to 1.00). 1

There was good or very good agreement between validation and primary data for patient (gender, kappa coefficient 0.99), operative (urgency 0.77; intent 0.75) and cancer staging (pT stage 0.93; pN stage 0.67) variables (Table S18) . Agreement for 30-day mortality (0.89) was also excellent, however, for 30-day major complication (0.63) the agreement was lower. 

Essential TNM Classification of Malignant Tumours (eTNM), as defined by the Union for International Cancer Control (UICC), for gastric cancer

A, Tumour through stomach wall with no nodal involvement

R+, Regional lymph node involvement

American Society of Anesthesiologists operative risk grade

BMI, body mass index

HIV, human immunodeficiency virus

James Glasbey MRCS 7 , Mark I. van Berge Henegouwen PhD 16

Dar Al-Shifa Hospital

Lifebox Foundation

National Institute for Health Research Global Health Research Unit on Global Surgery

Visceral Surgery Unit, Department of Surgery and Surgical Specialties, Faculty of Health Sciences

Department of Anesthesia & Perioperative Medicine, and Centre for Medical Evidence, Decision Integrity & Clinical Impact

Acute Care Surgery Unit, Department of Surgery

Global Surgery Research Centre

Exeter Surgical Health Services Research Unit (HeSRU), Royal Devon and Exeter Hospital

KAM: Study design, data collection, data analysis, data interpretation, and writing. RLM: Data collection DM: Study design, data interpretation, and writing. DN: Study design, data collection, data interpretation, and writing. LN: Data analysis and data interpretation. FN: Data collection, data interpretation, and writing. FP: Study design, data collection, data analysis, data interpretation, and writing. TDP: Data collection, data interpretation, and writing. RP: Study design, data analysis, data interpretation, and writing. AUQ: Study design, data collection, and manuscript revisions. ARM: Study design, data collection, data analysis, data interpretation, and writing. AMR: Data analysis and data interpretation. CAS: Study design, data analysis, data interpretation, and writing. JS: Data interpretation and writing. NJS: Study design, data collection, data analysis, data interpretation, and writing. RTS: Study design, data collection, and data interpretation. ST: Study design, data collection

Berge Henegouwen reports personal fees from Mylan, personal fees from Alesi Surgical, personal fees from Johnson and Johnson, grants and non-financial support from Stryker, personal fees from Medtronic, grants from Olympus, outside the submitted work

Brocklehurst reports grants and personal fees from MRC, grants from MRC, NIHR HTA, Wellcome Trust, personal fees from AG Biotest, outside the submitted work

Kingham reports personal fees from Olympus Surgical outside the submitted work

Arben Gjata; Argentina: Maria Marta Modolo

Ade Waterman; Belgium: Dominique Vervoort

Venerand Barendegere; Cameroon: Gerald Ekwen; Canada: Arnav Agarwal, Anna Dare; China: Qinyang Liu; Colombia

Kalisya Luc Malemo, Jacques Bake; Croatia: Jakov Mihanovic; Czech Republic: Kamila Kunčarová

Jyri Teras; Finland: Aristotelis Kechagias; France: Alexis P Arnaud

Justas Zilinskas; Madagascar: John Whitaker; Malawi: Precious Malemia; Malaysia: Yong Yong Tew; Malta: Elaine Borg

Philippines: Marie Carmela Lapitan; Poland: Piotr Major; Portugal: Joana Simões, António Sampaio Soares; Romania: Matei Razvan Bratu

Saudi Arabia: Ahmad Gudal

Anmar Homeida; Sweden: Yucel Cengiz; Switzerland: Daniel Clerc; Syrian Arab Republic: Muhammad Alshaar; Tunisia: Hanen Bouaziz; Turkey: Yuksel Altinel

Ahsan Ashfaq; United States: Ijeoma Azodo; Uruguay: Gabriela Wagner, Ivan Trostchansky; Zambia: Mayaba Maimbo, David Linyama. Local Collaborators * denotes Hospital Lead Albania

General Hospital of Vienna)

Yacoubou Imorou Souaibou

Omphile Tlhomelang (Princess Marina Hospital)

Burundi: Carlos Nsengiyumva (Kamenge Military Hospital)

The Ottawa Hospital)

Jacques Bake, Justin Tsandiraki (HEAL Africa Hospital)

Josip Samardžić (General Hospital Dr

Ales Paclik (The General University Hospital in Prague)

Amany Hossam el-din Zakaria

Mohamed Attia, Mohamed Balata

Nourhan Semeda, Hind I. Shalaby (National Cancer Institute)

Jyri Teras, Toomas Ümarik

Aristotelis Kechagias, Arto Turunen (Kanta-Hame Central Hospital)

Patrick's Hospital)

Greece: Dimitrios Balalis*, Dimitrios Korkolis

Konstantinos Papadopoulos* (General Hospital of Nikaia)

Stylianos Germanos, Evangelos Iliopoulos

Panagiotis Karathanasis, Nikolaos Michalopoulos, Charalampos Theodoropoulos, Dimitrios Theodorou

Alexandros Papalampros, Dimitrios Schizas, Athanasios Syllaios, Ekaterini Christina Tampaki*, Antonios Tsimpoukelis

Marton Benke, Kristof Illes, Balint András Kokas, Réka Szabó

Cliff Wanniang (North Eastern Indira Gandhi Regional Institute of

Sanjeev Parshad (Pandit Bhagwat Dayal Sharma Post Graduate Institute of

Iraq: Mazin A. Abdulla (Basra Teaching Hospital)

Azienda Ospedaliera Regionale 'San Carlo')

Basso (Azienda Per L'assistenza Sanitaria N. 5 Friuli Occidentale)

Guglielmo Niccolò Piozzi

Diego Sasia (Santa Croce and Carle Hospital)

Cyrine Katanani, Ra'fat Tawalbeh

Lithuania: Marijus Ambrazevicius*, Nerijus Kaselis, Migle Stakyte

Sarunas Dailidenas, Vitalijus Eismontas, Migle Kybransiene, Vitalija Nutautiene, Narimantas Samalavicius, Dainius Simcikas*, Algirdas Slepavicius, Albinas Tamosiunas, Nerijus Ubartas, Paulius Zeromskas

Juozas Kutkevičius, Aurimas Opolskis, Audrius Parseliunas, Andrejus Subocius, Donatas Venskutonis, Egle Virbickaite

Vygintas Šlenfuktas, Monika Sudeikyte, Algimantas Tamelis, Tomas Vanagas*, Žygimantas Žumbakys

Audrius Dulskas, Justas Kuliavas

Mindaugas Šatkauskas

Marius Kryzauskas, Vytautas Lipnickas, Gabija Makūnaitė

Syariz Ezuan Sulaiman

Philipp Plarre (Welwitschia Hospital)

Stijn Vlek (Zaans Medisch Centrum)

Arinzechukwu Mosanya (Obafemi Awolowo University Teaching Hospitals Complex Wesley Guild Hospital Unit)

Shahzad Hussain Waqar (The Pakistan Institute of Medical Sciences)

Yanal Nubani, Abdelrahman Rabee, Mohammad Sa'deh

Balqees Mohamad, Mhammed Rawhi (Beit Jala Governmental Hospital

Ahmed Nazzal, Ranin Nazzal (The Martyr Dr

Alcides Ylatoma Díaz* (Hospital Nacional Almanzor Aguinaga Asenjo)

Leonor Matos* (Centro Hospitalar Entre o Douro e Vouga)

Inês Isabel Sampaio da Nóvoa Gomes Miguel

André Graça e Magalhães

Bárbara Vieira* (Hospital de Santo Espirito da ilha Terceira)

Filipa Taré (Hospital Doutor

João Ribeiro (Hospital Prof. Doutor Fernando Fonseca

Miguel Morgado (Hospital Vila Franca de Xira)

Armen Vardanyan* (State Scientific Centre of Coloproctology)

Isaac Ndayishimiye (Rwanda Military Hospital)

Maahir Kariem (Mitchell's Plain District Hospital)

Reantha Pillay, Leandi Steynfaardt (New Somerset Hospital)

Laia Torrent Jansà (Hospital del Mar)

Laura Patricia Zorrilla Matilla

Pramodh Chandrasinghe, Sumudu Kumarage, Nimeshi Wijekoon Arachchilage

Teaching Hospital Anuradhapura)

Sotirios Ntaoulas, Michail Outos, Georgios Peros*, Hanna Podolska-Skoczek

Gökalp Kağan Kurtoğlu, Volkan Ozben, Berk Baris Ozmen

Kizito Hospital)

Volodimir Tyselskiy (Kyiv Regional Clinical Hospital)

Meical Povey (Countess of Chester Hospital)

Edgaras Smolskas (King's College Hospital)

Fahema Nadira (Princess Alexandra Hospital)

Austria: Julia Jedamzik (General Hospital of Vienna)

Tainá Santos Bezerra (Hospital

Cambodia: Sovannarith Oum (World Mate Emergency Hospital)

Arnav Agarwal (Sunnybrook Hospital)

General Hospital Dr

Zadar General Hospital)

Amgad Hegazi

Slezská nemocnice v Opavě

Vladimir Fryba (The General University Hospital in Prague)

Estonia: Sandra Teppo (The North Estonia Medical Centre)

Pasi Pengermä (Kanta-Hame Central Hospital)

Patrick's Hospital)

Konstantinos Perivoliotis (General University Hospital of Larissa)

Konstantinos Galanos-Demiris

Guatemala: Fernanda Ayau

Deepender Wason (Pandit Bhagwat Dayal Sharma Post Graduate Institute of

Indonesia: Ervandy Rangganata (Dr Cipto Mangunkusumo National General Hospital)

Italy: Margherita Pinto (Azienda Ospedaliera Regionale 'San Carlo')

Universitá della Campania 'Luigi Vanvitelli

Lithuania: Vilius Syminas

Wan Farahiyah Wan Muhmad (Hospital Tuanku Ja'afar)

Instituto Nacional de Ciencias Médicas y Nutrición 'Salvador Zubirán')

Pakistan: Maliha Nadeem (Ganga Ram Hospital)

Ibrahim Mousa (Rafidia Hospital)

Hospital de Clínicas, II Cátedra de Clínica Quirúrgica

Centro Hospitalar do Baixo Vouga)

Hospital de Santo Espirito da ilha Terceira)

Inês Mónica (Hospital Distrital da Figueira da Foz)

João Louro (Hospital Geral -Centro Hospitalar de Coimbra)

Nuno Miguel Freitas Oliveira (Hospital Vila Franca de Xira)

Unidade Local de Saude de Matosinhos -Hospital Pedro Hispano)

Russian Federation: Dmitry Shakhmatov (State Scientific Centre of Coloproctology)

Rwanda: Yves Nezerwa (Rwanda Military Hospital)

Mitchell's Plain District Hospital)

Sudan: Tarig Idris (Ibrahim Malik Teaching Hospital)

Malin Blomqvist (Vrinnevi Hospital)

Evrim Savli (Samsun Training and Research Hospital)

Ukraine: Andrii Diachenko (Dnepropetrovsk Regional

Vladislav Hordoskiy (Kyiv Regional Clinical Hospital)

Heather Curry

Hairmyres Hospital)

Ninewells Hospital)

Southmead Hospital)